BioNTech SE’s (NASDAQ:BNTX) Quiet Period Set To End on November 19th

BioNTech’s (NASDAQ:BNTX) quiet period will end on Tuesday, November 19th. BioNTech had issued 10,000,000 shares in its IPO on October 10th. The total size of the offering was $150,000,000 based on an initial share price of $15.00. During BioNTech’s quiet period, insiders and underwriters that worked on the IPO are prevented from issuing any research reports or earnings estimates for the company because of regulations issued by the Securities and Exchange Commission. Following the expiration of the company’s quiet period, it’s expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

A number of equities research analysts recently commented on the company. Leerink Swann assumed coverage on BioNTech in a research report on Monday, November 4th. They issued an “outperform” rating for the company. Wolfe Research assumed coverage on BioNTech in a research report on Tuesday, November 5th. They issued an “outperform” rating and a $21.00 price target for the company. Canaccord Genuity assumed coverage on BioNTech in a research report on Monday, November 4th. They issued a “buy” rating and a $22.00 price target for the company. JPMorgan Chase & Co. assumed coverage on BioNTech in a research report on Monday, November 4th. They issued an “overweight” rating and a $23.00 price target for the company. Finally, Bank of America assumed coverage on BioNTech in a research report on Monday, November 4th. They issued a “buy” rating and a $21.00 price target for the company. Eight equities research analysts have rated the stock with a buy rating, BioNTech currently has a consensus rating of “Buy” and an average target price of $22.17.

Shares of BioNTech stock opened at $19.24 on Friday. BioNTech has a 1 year low of $12.52 and a 1 year high of $21.99.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other diseases. The company is involved in developing FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 for prostate cancer; BNT113 that is in Phase I clinical trial to treat HPV+ head and neck cancers; BNT114, which is in Phase I clinical trial for triple negative breast cancer; and BNT115 and BNT116 to treat other cancers, including ovarian cancer.

Further Reading: 52-Week High/Low Prices For Stock Selection

Receive News & Ratings for BioNTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNTech and related companies with MarketBeat.com's FREE daily email newsletter.